Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1641 1644 1647
This examiner grants 62% of resolved cases
Hannah Louise Sunshine is a patent examiner in Tech Center 1600, specifically within Art Unit 1618. The examiner has 40 resolved cases. These cases result in an allowance rate of 62.5 percent. This 62.5 percent figure represents the frequency of applications that reach issuance. Practitioners can use this rate to understand the historical probability of success for applications assigned to this examiner.
The data includes an interview lift of 24.9 percent. This positive value indicates that applications with an interview have a higher allowance rate than those without one. Because the lift is 24.9 percent, practitioners should consider how an interview affects the prosecution strategy. This metric suggests that verbal communication is associated with an increase in the likelihood of a grant for this examiner.
The median days to allowance for this examiner is 1394. This 1394 figure marks the middle point of the time from filing to patent issuance. With 40 resolved cases, this median provides a timeline for expected prosecution duration in Tech Center 1600. These statistics allow for data-grounded planning regarding both the outcome and the timing of patent applications in Art Unit 1618.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17777363 | COMPOSITIONS AND METHODS FOR OPTOGENETIC IMMUNOTHERAPY | Non-Final OA | University of Massachusetts |
| 17763116 | RECEPTORS WITH HETEROLOGOUS TRANSMEMBRANE DOMAIN | Non-Final OA | The Regents of the University of California |
| 18571397 | METHODS FOR TREATING OBSTRUCTIVE SLEEP APNEA | Non-Final OA | Eli Lilly and Company |
| 17584642 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18019460 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | Juno Therapeutics, Inc. |
| 17439124 | CYTOKINE-BASED IMMUNE CELLS AND IMMUNOTHERAPEUTIC USE THEREOF | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17918644 | CHIMERIC MYD88 RECEPTORS | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 18271026 | NATURAL KILLER CELLS ENGINEERED TO REDUCE OR ELIMINATE CBL-B AND USES THEREOF | Non-Final OA | City of Hope |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy